Abstract Context The European Association of Urology (EAU) panel on Non–muscle-
invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non …

Non-muscle invasive bladder cancer (NMIBC) is a heterogeneous population of tumours
accounting for 80% of bladder cancers. Over the years, the management of this disease has …

Objective To summarize the discussion at a public workshop, cosponsored by the US Food
and Drug Administration (FDA) and the American Urological Association, reviewing potential …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …

Objective: To propose updated French guidelines for non-muscle invasive (NMIBC) and
muscle-invasive (MIBC) bladder cancers. Methods: A Medline search was achieved …

Conflicting results of survival outcomes for primary and secondary muscle-invasive bladder
cancer (MIBC) have been reported in previous studies. Primary MIBC is defined as …

Seventy percent of newly diagnosed bladder cancers are classified as non‐muscle‐invasive
bladder cancer (NMIBC) and are often associated with high rates of recurrence that require …

Purpose of Review BCG is the gold standard agent used in high-risk non-muscle-invasive
bladder cancer (NMIBC) that is amenable to bladder sparing management. However, recent …

Objective To update the ccAFU recommendations for the management of bladder tumours
that do not infiltrate the bladder muscle (NBMIC). Methods A systematic review (Medline) of …

EAU GUIDELINES ON MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER Page 1
Muscle-invasive and Metastatic Bladder Cancer 34 EAU GUIDELINES ON MUSCLE-INVASIVE …